糖尿病慢性肢体威胁性缺血孤立踝下介入的结果
本研究回顾性分析2007-2017年因组织缺损接受孤立踝下介入的109例糖尿病患者(平均65岁,153条血管),技术成功率81%,30天主要不良心血管事件0%。5年临床有效性25%±7%,无截肢生存率33%±8%,免于主要不良肢体事件27%±9%。
要点
- 孤立踝下介入在高危肢体中短期结果可接受,30天主要不良心血管事件为0%。
- 5年无截肢生存率仅33%±8%,长期预后受基础疾病进程影响。
- 术后足部流出道评分<7、无终末期肾病、WIfI分期<3与无截肢生存相关。
核心结论
- 孤立踝下介入可在高危肢体中成功实施,短期结果可接受。
- 长期无截肢生存率仍较差,归因于基础疾病进程。
研究设计与样本
- 回顾性查询2007-2017年因组织缺损(WIfI 1-3期)行下肢血管内介入的数据库。
- 纳入109例(48%男性,平均年龄65岁,153条血管)接受孤立踝下介入(足背动脉、内侧和外侧跗动脉)的患者,排除合并股浅动脉和胫动脉介入者。
- 按患者进行意向性治疗分析。
主要发现
- 技术成功率为81%,中位每例治疗1条血管。
- 30天主要不良心血管事件率为0%。
- 无需截肢者3个月伤口愈合率为76%。
- 5年临床有效性为25%±7%,5年无截肢生存率为33%±8%,5年免于主要不良肢体事件为27%±9%。
关键数值与推荐
- 伤口愈合的预测因素包括足部流出道评分改善(<7)、无感染、直接目标血管区血运重建和无终末期肾病。
- 无截肢生存的预测因素包括无显著冠心病、术后足部流出道评分<7(良好流出道)、WIfI分期<3和无终末期肾病。
- 53%的患者有慢性肾功能不全(其中47%接受血液透析),多数患者为WIfI 3期。
临床怎么用
- 对于糖尿病合并组织缺损的高危肢体,可考虑孤立踝下介入,但需告知长期无截肢生存率较低。
- 关注术后足部流出道评分、感染控制、目标血管区直接血运重建及终末期肾病状态以改善预后。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Inframalleolar disease is present in many diabetic patients presenting with tissue loss. The aim of this study was to examine the patient-centered outcomes after isolated inframalleolar interventions. METHODS: A database of patients undergoing lower extremity endovascular interventions for tissue loss (critical limb-threatening ischemia, Wound, Ischemia, and foot Infection [WIfI] stage 1-3) and a de novo intervention on the index limb between 2007 and 2017 was retrospectively queried. Those patients with isolated inframalleolar interventions on the dorsalis pedis and medial and lateral tarsal arteries were identified. Patients with concomitant superficial femoral artery and tibial interventions were excluded. Intention-to-treat analysis by patient was performed. Patient-oriented outcomes of clinical efficacy (absence of recurrent symptoms, maintenance of ambulation, and absence of major amputation), amputation-free survival (AFS; survival without major amputation), and freedom from major adverse limb events (above-ankle amputation of the index limb or major reintervention [new bypass graft, jump or interposition graft revision]) were evaluated. RESULTS: There were 109 patients (48% male; average age, 65 years; 153 vessels) who underwent isolated inframalleolar interventions for tissue loss. All patients had diabetes, and 53% had chronic renal insufficiency (47% of these were on hemodialysis). The majority of the patients had WIfI stage 3 disease. Technical success was 81%, with a median of one vessel treated per patient. Thirty-four percent of interventions were a direct revascularization of the intended angiosome in the foot. The 30-day major adverse cardiovascular event rate was 0%. The majority of patients underwent some form of planned forefoot surgery (single digit, multiple digits, ray or transmetatarsal amputation). Wound healing at 3 months in those not requiring amputation was 76%. Predictors for wound healing were improved pedal runoff score (<7), absence of infection, direct angiosome revascularization, and absence of end-stage renal disease. Those in whom the primary wounds or the initial amputation site failed to heal ultimately underwent below-knee amputations. The clinical efficacy was 25% ± 7% (mean ± standard error of the mean) at 5 years. The 5-year AFS rate was 33% ± 8%, and the 5-year freedom from major adverse limb events was 27% ± 9%. On Cox proportional multivariate analysis, predictors for AFS were absence of significant coronary disease, postprocedure pedal runoff score <7 (good runoff), WIfI stage <3, and absence of end-stage renal disease. CONCLUSIONS: Inframalleolar intervention can be successfully performed in high-risk limbs with acceptable short-term results. However, long-term AFS remains poor because of the underlying disease process.
引用
- Cheun TJ, Jayakumar L, Sideman MJ, et al. Outcomes of isolated inframalleolar interventions for chronic limb-threatening ischemia in diabetic patients. J Vasc Surg. 2020. PMID: 32081478. doi:10.1016/j.jvs.2019.07.094
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。